BRUSSELS--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from PROGRESS, the long-term extension study of the investigational regimen ORKAMBI™ (lumacaftor/ivacaftor). The ongoing extension study enrolled people with cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation and completed 24 weeks of treatment in the Phase 3 TRAFFIC and TRANSPORT studies (lumacaftor/ivacaftor combination and placebo treatment groups) and met certain other eligibility criteria.
Help employers find you! Check out all the jobs and post your resume.
